An Open-Label, Multiple-Dose, Dose- Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

Protocol No

VMONCOLOGY-VMO-01C

Principal Investigator

Sailaja Kamaraju

Phase

I

Summary

The major purposes of this study are to determine the maximum dose of the study drug that can be tolerated in humans, and once this dose is found, if it has any effect in patients with solid tumors or lymphoma.

Description

This is a Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL

Sub Category

Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Head and Neck Cancers, Gynecologic Cancers

ClinicalTrials.gov

go to website